Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02599402
Title Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications

melanoma

Therapies

Ipilimumab + Nivolumab

Nivolumab

Age Groups: adult | senior
Covered Countries


No variant requirements are available.